Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”

키워드

참고문헌 (18)

1. Yeh ML, "From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease : Updates of nomenclature and impact on clinical trials", Clin Mol Hepatol, 29, pp.969~972 (2023)
2. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease(MASLD)", J Hepatol, 81, pp.492~542 (2024)
3. Lee KC, "Pathogenesis and treatment of nonalcoholic steatohepatitis and its fibrosis", Clin Mol Hepatol, 29, pp.77~98 (2023)
4. Newsome PN, "Incretins(GLP-1 receptor agonists and dual", triple agonists)and the liver, 2023, pp.79, 1557~1565
5. Park MJ, "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease : A network meta-analysis", Clin Mol Hepatol, 29, pp.693~704 (2023)
6. Sanyal AJ, "A phase 2 randomized trial of survodutide in MASH and fibrosis", N Engl J Med, 391, pp.311~319 (2024)
7. Loomba R, "Tirzepatide for metabolic dysfunctionassociated steatohepatitis with liver fibrosis", N Engl J Med, 391, pp.299~310 (2024)
8. Newsome PN, "A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis", N Engl J Med, 384, pp.1113~1124 (2021)
9. Musso G, "Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis : A meta-analysis", JAMA Intern Med, 177, pp.633~640 (2017)
10. Harrison SA, "Evaluation of PXL065-deuterium-stabilized(R)-pioglitazone in patients with NASH : A phase II randomized placebo-controlled trial(DESTINY-1)", J Hepatol, 78, pp.914~925 (2023)
11. Ye Q, "Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 5, pp.739~752 (2020)
12. Gastaldelli A, "Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes(SURPASS-3 MRI) : a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3trial", Lancet Diabetes Endocrinol, 10, pp.393~406 (2022)
13. Jastreboff AM, "Triple-hormone-receptor agonist retatrutide for obesity-A phase 2 trial", N Engl J Med, 389, pp.514~526 (2023)
14. Urva S, "LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes : a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multipleascending dose trial", Lancet, 400, pp.1869~1881 (2022)
15. Harrison SA, "A Phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis", N Engl J Med, 390, pp.497~509 (2024)
16. Ratziu V, "Rational combination therapy for NASH : Insights from clinical trials and error", J Hepatol, 78, pp.1073~1079 (2023)
17. Alkhouri N, "Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis : A randomised, open-label phase II trial", J Hepatol, 77, pp.607~618 (2022)
18. Harrison SA, "Safety and efficacy of efruxifermin in combination with a GLP-1 receptor agonist in patients with NASH", MASH and type 2 diabetes in a randomized phase 2 study, 2024, ~